MD783Z - Метод лечения хронического атрофического гастрита - Google Patents
Метод лечения хронического атрофического гастрита Download PDFInfo
- Publication number
- MD783Z MD783Z MDS20130164A MDS20130164A MD783Z MD 783 Z MD783 Z MD 783Z MD S20130164 A MDS20130164 A MD S20130164A MD S20130164 A MDS20130164 A MD S20130164A MD 783 Z MD783 Z MD 783Z
- Authority
- MD
- Moldova
- Prior art keywords
- treatment
- day
- atrophic gastritis
- orally
- chronic atrophic
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 208000016644 chronic atrophic gastritis Diseases 0.000 title claims abstract description 6
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 235000012054 meals Nutrition 0.000 claims abstract description 13
- 239000002113 nanodiamond Substances 0.000 claims abstract description 11
- 238000001802 infusion Methods 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 244000082872 Alchemilla vulgaris Species 0.000 claims abstract description 7
- 235000000008 Alchemilla vulgaris Nutrition 0.000 claims abstract description 7
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241001072961 Pogostemon Species 0.000 claims abstract description 5
- 239000001738 pogostemon cablin oil Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 208000006994 Precancerous Conditions Diseases 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010015137 Eructation Diseases 0.000 description 2
- 235000014066 European mistletoe Nutrition 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 240000002505 Pogostemon cablin Species 0.000 description 2
- 235000011751 Pogostemon cablin Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 240000007313 Tilia cordata Species 0.000 description 2
- 241000221012 Viscum Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 241000983746 Saccharina latissima Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к медицине, в частности к гастрологии, и может быть использовано для лечения хронического атрофического гастрита.Согласно изобретению, заявленный метод состоит в том, что вводят 200 мл озонированной смеси на основе масла Pogostemon patchouli, содержащей наноалмазы размером 4…10 нм, в концентрации 10-9…10-10 г/л с концентрацией озона 8000…10000 мкг/л, per os, два раза в день, за час до еды, и одновременно 200 мл настойки Alchemilla vulgaris L., per os, один раз в день, за 20 мин до еды, курс лечения составляет 2 месяца.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20130164A MD783Z (ru) | 2013-10-08 | 2013-10-08 | Метод лечения хронического атрофического гастрита |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20130164A MD783Z (ru) | 2013-10-08 | 2013-10-08 | Метод лечения хронического атрофического гастрита |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD783Y MD783Y (ru) | 2014-06-30 |
| MD783Z true MD783Z (ru) | 2015-01-31 |
Family
ID=51022559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20130164A MD783Z (ru) | 2013-10-08 | 2013-10-08 | Метод лечения хронического атрофического гастрита |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD783Z (ru) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002535A1 (en) * | 1989-08-11 | 1991-03-07 | Basil, Inc. | Cancer prevention composition and method |
| RU2034560C1 (ru) * | 1993-05-18 | 1995-05-10 | Товарищество с ограниченной ответственностью "Фитолон" | Средство для профилактики рака "кламин" |
| MD3773G2 (ru) * | 2008-05-30 | 2009-09-30 | Ион МЕРЕУЦЭ | Средство для лечения предраковых поражений кожных покровов и слизистых оболочек |
| MD3972C2 (ru) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Средство и метод лечения предраковых состояний |
| MD611Z (ru) * | 2012-02-14 | 2013-10-31 | Раиса МЕРЕУЦА | Метод лечения хронического атрофического гастрита |
-
2013
- 2013-10-08 MD MDS20130164A patent/MD783Z/ru not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002535A1 (en) * | 1989-08-11 | 1991-03-07 | Basil, Inc. | Cancer prevention composition and method |
| RU2034560C1 (ru) * | 1993-05-18 | 1995-05-10 | Товарищество с ограниченной ответственностью "Фитолон" | Средство для профилактики рака "кламин" |
| MD3773G2 (ru) * | 2008-05-30 | 2009-09-30 | Ион МЕРЕУЦЭ | Средство для лечения предраковых поражений кожных покровов и слизистых оболочек |
| MD3972C2 (ru) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Средство и метод лечения предраковых состояний |
| MD611Z (ru) * | 2012-02-14 | 2013-10-31 | Раиса МЕРЕУЦА | Метод лечения хронического атрофического гастрита |
Also Published As
| Publication number | Publication date |
|---|---|
| MD783Y (ru) | 2014-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016370126B2 (en) | Medicine composition for treating leukemia and preparation method therefor | |
| CN102697893A (zh) | 黑树莓提取物在制备治疗胃癌药物中的应用 | |
| EP3701970A2 (en) | Immunity-boosting agent, immuno-therapeutic anti-cancer agent, and anti-cancer therapy adverse effect mitigating agent containing anthocyanin-fucoidan complex as active ingredient | |
| RU2533446C2 (ru) | Способ повышения физической выносливости организма в условиях ультрафиолетового облучения | |
| EA027651B1 (ru) | Биологически активная добавка к пище для нормализации функции щитовидной железы | |
| Bose et al. | In vitro evaluation of anti-proliferative activity of protein from Litchi chinensis honey against human cervical cancer cell line (HeLa) | |
| CN104623215B (zh) | 一种抗肿瘤的药物组合物 | |
| MD783Z (ru) | Метод лечения хронического атрофического гастрита | |
| CN102114065B (zh) | 具有防治癌症作用的金钱草与雷公藤中药组合物及其应用 | |
| RU2443427C1 (ru) | Антигельминтное средство | |
| CN101732377A (zh) | 具有抗癌作用的刺人参叶总皂苷提取物的制备方法 | |
| CN102232957B (zh) | 3-乙酰氧基-8,24-羊毛甾二烯-21-酸在制备预防、治疗肝癌或乳腺癌药物中的用途 | |
| RU2836810C1 (ru) | Растительные ветеринарные композиции против нематод | |
| US20200000847A1 (en) | Pharmaceutical composition for treating leukemia and method for preparing the same | |
| CN103432247B (zh) | 一种用于治疗缺血性中风的中药有效部位组合物及其制备方法 | |
| JP7588388B2 (ja) | Ｉｌ－１８の産生抑制剤 | |
| CN109010495A (zh) | 一种中药组合物及其制备方法和应用 | |
| BR102021024155A2 (pt) | Uso de uma solução/emulsão a partir de ziziphus cotinifolia reissek no tratamento dos transtornos da ansiedade | |
| TWI674894B (zh) | 治療黑色素瘤之藥劑及其應用 | |
| KR20040026274A (ko) | 항암 및 제암 효과를 갖는 건강보조식품 및 이의 제조방법 | |
| BG4014U1 (bg) | Състав на сироп предотвратяващ негативните странични ефекти от химиотерапия | |
| KR101359528B1 (ko) | 봉독과 로얄제리를 유효성분으로 함유하는 방사선 방호용 조성물 | |
| MD611Z (ru) | Метод лечения хронического атрофического гастрита | |
| Kovalev et al. | Grounding of semisolid medicinal forms production on nature components | |
| CN118236444A (zh) | 一种中药组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |